Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Bausch Health reported $2.26 billion in revenue for Q1 2025, a year-over-year increase of 4.9%, with EPS remaining unchanged at $0.59 compared to the previous year [1] - The revenue fell short of the Zacks Consensus Estimate of $2.27 billion, resulting in a surprise of -0.54%, while the EPS missed the consensus estimate of $0.83 by -28.92% [1] Revenue Breakdown - Bausch + Lomb - Ophthalmic Pharmaceuticals: $267 million, below the estimate of $285.29 million, with no year-over-year change [4] - Solta Medical: $113 million, exceeding the estimate of $105.12 million, representing a year-over-year increase of 28.4% [4] - Bausch + Lomb - Vision Care: $656 million, slightly below the estimate of $657.80 million, with a year-over-year increase of 3.3% [4] - Total Bausch Health (excluding B+L): $1.12 billion, matching the estimate, with a year-over-year increase of 6.5% [4] - Total Bausch + Lomb revenues: $1.14 billion, below the estimate of $1.16 billion, with a year-over-year increase of 3.5% [4] - Diversified Products: $205 million, exceeding the estimate of $201.28 million, with a year-over-year increase of 1.5% [4] - Bausch + Lomb - Surgical: $214 million, slightly above the estimate of $212.34 million, with a year-over-year increase of 8.6% [4] - Salix: $542 million, below the estimate of $544.67 million, with a year-over-year increase of 8.6% [4] - International revenues: $262 million, below the estimate of $267.63 million, with a year-over-year decrease of 1.1% [4] - Product sales: $2.23 billion, slightly below the estimate of $2.24 billion, with a year-over-year increase of 4.6% [4] - Other revenues: $32 million, exceeding the estimate of $22.60 million, with a year-over-year increase of 33.3% [4] - Diversified Products - Dentistry: $23 million, below the estimate of $23.77 million, with a year-over-year decrease of 4.2% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]